Back to results
US 2018/0002664 A1Published application
B cells for in vivo delivery of therapeutic agents
OwnerMatthew Rein SCHOLZ, Eric J. HERBIG +2inventors
InventorsMatthew Rein SCHOLZ, Eric J. HERBIG, Mei XU, Rian DE LAAT
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to genetically modified B cells, including memory cells, differentiated to plasmablasts or plasma cells useful for long tem in vivo expression of a transgene, such as a specific antibody or other protein therapeutic. Also disclosed are methods of producing the cells and methods of treatment.
Claims33
A method of producing a modified B cell composition comprising:
- (a) isolating pan-B cells, memory B cells, switched memory B cells, or plasma cells from a sample, thereby obtaining an isolated B cell population,
- (b) culturing the isolated B cell population in vitro with one or more B cell activating factors, thereby obtaining an expanded B cell population,
- (c) transfecting the expanded B cell population with a transgene, and
- (d) differentiating the expanded B cell population in vitro with one or more B cell activating factors, thereby obtaining a modified B cell composition.
1 more element
Dependencies are inferred from the claim text.